Insys Therapeutics NASDAQ INSY 160 might have a problem on its hands This week the FDA requested that Endo International NASDAQ ENDP remove its opioid medication Opana ER from the market and that news raises the question Who s next If Insys Therapeutics
June 11, 2017 at 12:01PM
from
No comments:
Post a Comment